论文部分内容阅读
在确定宫颈癌治疗计划时,了解癌的范围是最重要的根据,虽然治疗前的分期对估计癌的范围很有帮助,但是双合诊所做的临床分期往往与术时所见很不一致,有人报道据此分期颇有误差。我们认为,测定血中的TA-4,方法简单、容易,对于预测宫颈癌的范围,有一定的价值。对于诊断为宫颈鳞状细胞癌开始用手术治疗的96个患者,术前2-5天取血标本,用放射免疫分析法测血中TA-4的水平。所有患者术前都根据国际妇产科协会的规定进行分期,术时根据手术所见和组织学检查来重新评价病变范围,对所有的患者术后至少
In determining the treatment plan for cervical cancer, understanding the extent of cancer is the most important basis. Although the pre-treatment stage is very helpful in estimating the scope of cancer, clinical staging done by Shuanghe clinics is often inconsistent with the findings at the time of surgery. According to the report staging error. We believe that the determination of blood TA-4, the method is simple and easy, for the prediction of the scope of cervical cancer, there is a certain value. For 96 patients diagnosed with cervical squamous cell carcinoma who started surgery, blood samples were taken 2-5 days before surgery and the level of TA-4 in the blood was measured by radioimmunoassay. All patients were staged preoperatively according to the rules of the International Association of Obstetrics and Gynecology. At the time of surgery, the patients were re-evaluated according to the surgical findings and histological examination, and at least